Organon Taps Biosimilar Architect Dominic Bégin to Lead Canadian Operations

KIRKLAND, QC – July 22, 2026 – Organon Canada has elevated one of its own founding leaders to its top post, appointing Dominic Bégin as President and Managing Director. The move signals a clear strategic doubling-down on the two pillars that define the company: expanding access to cost-saving biosimilars and addressing unmet needs in women's health. Bégin, the architect behind the firm's highly successful biosimilars division, now takes the reins of the entire Canadian operation, a move that suggests a strategy of accelerated growth and deeper integration into the Canadian healthcare fabric.

A Proven Leader Takes the Helm

Mr. Bégin is no newcomer to the complexities of the Canadian pharmaceutical market. With over 25 years of industry experience, he was a pivotal member of the leadership team that launched Organon in Canada following its spin-off in 2021. His tenure has been marked by a demonstrable ability to turn strategy into tangible results, most notably in his recent role as Executive Director of the Biosimilars and Biologics franchise.

Under his guidance, the division achieved sustained double-digit growth, cementing Organon's position as a market leader in the Canadian biosimilars space. This success was not merely a commercial victory; it directly contributed to expanding patient access to more affordable treatments and generated significant savings for Canada's provincial healthcare systems. His deep experience spans roles in sales, marketing, market access, and corporate strategy at Merck Canada prior to joining Organon, giving him a comprehensive view of the industry.

"Dominic is a values-driven leader with a consistent track record of delivering results while building inclusive, purpose-driven teams," said Litsa Spiridonakos, Head of Human Resources, Organon Canada, in the official announcement. "His strategic mindset, deep industry expertise, and collaborative approach will be critical as we continue to expand access to medicines and advance our leadership in women's health."

For his part, Bégin expressed his commitment to the company's foundational goals. "I am honoured to take on this role and continue building on the strong foundation established since Organon's launch in Canada," he stated. "Together with our leadership team and colleagues across the organization, we will focus on expanding Organon's presence in Canada, unlocking new opportunities, and helping expand access to healthcare options for patients nationwide."

The Biosimilar Imperative: Driving Affordability and Growth

Bégin's appointment is strategically significant, particularly given his background. Placing the leader who built its biosimilar powerhouse into the top job underscores the critical importance of this sector to Organon's future. Biosimilars—highly similar and cost-effective versions of original biologic drugs—are a cornerstone of healthcare sustainability in Canada. By offering more affordable alternatives for treating conditions from cancer to autoimmune diseases, they free up crucial funds within provincial drug plans that can be reinvested into novel, innovative therapies.

The Canadian market has become increasingly receptive to these products. As of mid-2025, Health Canada had approved over 60 biosimilars, and nearly all provinces have implemented "switching" policies that transition patients from originator biologics to biosimilars, accelerating adoption and savings. Organon has been at the forefront of this shift, a position solidified by Bégin's franchise leadership.

The competitive landscape is robust, with industry association Biosimilars Canada representing key players like Sandoz, Teva, and Apotex. Notably, Bégin's predecessor, Michael Casia, serves as the chair of this very association, highlighting Organon’s deep institutional commitment to shaping the policy and market environment for biosimilars. Bégin’s promotion ensures a continuity of this influential leadership, leveraging his proven expertise to navigate a competitive field and partner with payers to maximize the value these medicines deliver.

Deepening the Commitment to Women's Health

Beyond biosimilars, Organon's core identity is its dedication to women's health—a mission to deliver "a better and healthier every day for every woman." This focus is not just a marketing slogan; it addresses a documented gap in Canadian healthcare. A recent McKinsey Health Institute report, often cited by Organon, found that Canadian women spend approximately 24% more of their lives in poor health compared to men. This "women's health gap" represents a significant unmet need and a strategic opportunity.

Under Bégin’s leadership, the company is expected to intensify its efforts in its key women's health franchises, which include contraception, fertility, and hormone therapy. His mandate will involve not only driving the commercial success of its portfolio of over 70 products but also championing a broader conversation about health equity.

This commitment is reflected internally as well. Organon Canada has earned the highest level of gender-parity certification from Women in Governance, a testament to its efforts to build a culture that mirrors its external mission. By fostering an inclusive and equitable workplace, the company reinforces the authenticity of its public-facing goal to improve the lives of women. Bégin's reputation for building "inclusive, purpose-driven teams" aligns perfectly with this corporate ethos, suggesting that the company's internal culture and external strategy will remain tightly linked.

Navigating the National Healthcare Ecosystem

Success in the Canadian pharmaceutical market requires more than just effective products; it demands sophisticated navigation of a complex, decentralized healthcare system. Organon has been an active voice in national health policy discussions, advocating for the development of a Pan-Canadian health strategy that includes robust policies for biosimilars and the long-awaited implementation of a national pharmacare program.

Bégin's appointment places a leader with deep Canadian roots and a history of building "trusted partnerships across the healthcare ecosystem" at the helm. This experience is invaluable for engaging with provincial payers, federal regulators like Health Canada, and influential bodies such as the pan-Canadian Pharmaceutical Alliance (pCPA). His collaborative approach will be essential in ensuring Organon's products achieve favorable reimbursement and market access, and that the company remains a constructive partner in policy development.

By promoting an insider who has been instrumental in the company’s Canadian success story, Organon is signaling stability and a sharpened focus. With Dominic Bégin leading the charge, Organon Canada is strategically positioned not only to expand its commercial footprint but also to act as a key partner in shaping a more sustainable and equitable healthcare system for all Canadians.